Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

WASHINGTON, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Sabin a multi-year contract with funding potential for up to $214 million to advance the development and production of single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

There are currently no licensed vaccines against Ebola Sudan and Marburg viruses, which cause hemorrhagic fever and kill approximately half the people infected.

BARDA, part of the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR), will initially invest approximately $35 million to produce up to 100,000 doses of Sabin’s Ebola Sudan virus (ChAd3-SUDV) vaccine. These vaccines may be used as part of ongoing U.S. preparedness efforts and in response to future global outbreaks.

The Sabin vaccine was the first to arrive in Uganda during the recent Ebola Sudan virus outbreak that caused 55 deaths after the World Health Organization included it as one of three vaccines for possible use in an outbreak trial in Uganda. The country declared the Ebola Sudan outbreak had ended on January 11, four months after the first confirmed case.

“Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment,” says Sabin Chief Executive Officer Amy Finan. “This new contract enables Sabin to produce up to 100,000 doses so the world is prepared in advance for future outbreaks.”

In addition to participating in recent outbreak activities, Sabin continues its Sudan development plan and has initiated Phase 2 clinical trial planning in Uganda and Kenya. Based on previous clinical trials, Sabin’s Ebola Sudan vaccine is safe and immunogenic, and in nonhuman primate studies has demonstrated rapid protection, durability up to 12 months, and efficacy.

In addition to Sabin’s ChAd3-SUDV vaccine, the contract also includes support to manufacture Sabin’s vaccine against Marburg virus (ChAd3-MARV), which would generate doses that could also be used in trials and in response to a possible Marburg virus outbreak. As recently as last July, two people in Ghana died after being infected with Marburg virus, reinforcing the urgent need for a vaccine.

The new contract leverages a partnership with BARDA that began in 2019, when the agency awarded Sabin another multi-year contract valued at $128 million to further the development of vaccines against both the Marburg and Ebola Sudan viruses.

“BARDA has been a supportive partner as we take these essential steps in pandemic preparedness,” said Finan. “The Ebola Sudan outbreak in Uganda underscored the critical need for readily available solutions. We’ll now have ample material to respond quickly to such an outbreak in the future.”

This project will be funded in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50123C00010.

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine.

About Ebola Sudan and Marburg

Ebola Sudan and Marburg are members of the filovirus family. Both can cause severe hemorrhagic fever in humans and nonhuman primates. No therapeutic treatment of these hemorrhagic fevers has been licensed to date. Marburg and Ebola viruses are transmitted to humans by infected animals, particularly fruit bats. Once a human is infected, the virus can spread to others through close personal contact or contact with bodily fluids. Isolation of infected people is currently the centerpiece of filovirus control.

Marburg was the first filovirus to be recognized in 1967 when outbreaks of hemorrhagic fever were reported in a few Europe-based laboratories including in the town of Marburg, Germany. Ebola was identified in 1976 when two simultaneous outbreaks occurred in northern Zaire (now the DRC) in a village near the Ebola River and in southern Sudan. The outbreaks involved what eventually proved to be two different species of Ebola virus; both were named after the nations in which they were discovered.

For media inquiries:

press@sabin.org

Media Contact:
Monika Guttman
Media Relations Specialist
Sabin Vaccine Institute
+1 (202) 662-1841
press@sabin.org

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/539c9127-e5d6-4b32-9e89-780f7461314b


Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines

THỦ THUẬT HAY

Hướng dẫn cập nhật iOS 11.2.5 chính thức

iOS 11.2.5 thực chất là bản update nguyên gốc từ iOS 11.2.5 beta 7 với cùng mã hiệu build 15D60. Và sau đây là những thay đổi đáng chú ý trên bản cập nhật này.

Đây là cách từ Windows 10 xuống Win 7 hoặc Win 8.1 không cần cài lại máy

Nhiều người sau khi cài đặt lên phiên bản Windows 10 rất muốn hạ cấp máy và trở về với Windows 7 và Windows 8.1. Tuy nhiên, ngoài việc cái lại toàn bộ máy tính chúng ta có cách nào không? Câu trả lời là Có...

Có thể chơi game kiếm tiền trên điện thoại? Đừng bỏ qua 4 tựa game này

Không dừng lại là những giây phút giải trí sau giờ làm việc, học tập mệt mỏi, căng thẳng. Game đang dần trở thành một cách thức để người chơi có thể thoả mãn đam mê nhưng vẫn kiếm được tiền thật.

4 lỗi phổ biến mà nhiều người vẫn hay mắc phải khi chụp ảnh

Với nhiều năm kinh nghiệm, nhiếp ảnh gia này đã chỉ ra 4 lỗi phổ biến về cách chụp mà nhiều người vẫn hay mắc phải khi chụp ảnh.

Những thủ thuật khi sử dụng Facebook mà có thể bạn chưa biết

Dù ứng dụng Facebook trên smartphone mang lại khá nhiều tiện lợi, cho phép truy cập ở bất kỳ nơi nào, nhưng đa số người dùng vẫn thích sử dụng máy tính để nhận đầy đủ hơn tiện ích từ Facebook.

ĐÁNH GIÁ NHANH

Đánh giá Meizu M3: “Ngon” trong tầm giá dưới 3 triệu đồng

Với thiết kế trẻ trung, cùng cấu hình phần cứng tốt, đi kềm với mức giá rẻ. Meizu M3 đang là lựa chọn khó có thể bỏ qua

Đánh giá màn hình UltraSharp 32 HDR PremierColor

UltraSharp 32 HDR PremierColor là một trong những sản phẩm màn hình mới của nhà sản xuất Mỹ nổi tiếng Dell. Đây chắc chắn sẽ trở thành một ước mơ mới của dân làm đồ họa chuyên nghiệp.

Range Rover Sport HSE 2019 có những điểm gì hấp dẫn?

Có giá bán khoảng 295.000 USD tại một số đại lý tư nhân, Range Rover Sport HSE 2019 là đối thủ trực tiếp của Porsche Cayenne S, Maserati Levante S và một số mẫu SUV hiệu năng cao khác đến từ Đức. Vậy đâu là điểm hấp